

# Myriad genetics®

## First Quarter 2026 Earnings Call

MAY 5, 2026

©2026 Myriad Genetics, Inc.



# Forward-looking statements and Non-GAAP financial measures

Some of the information presented here today contains projections or other forward-looking statements regarding future events or the future financial performance of the Company.

## FORWARD-LOOKING STATEMENTS AND DISCLAIMERS

These statements are based on management's current expectations and the actual events or results may differ materially and adversely from these expectations. We refer you to the documents the Company files from time to time with the Securities and Exchange Commission, specifically, the Company's annual report on Form 10-K, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. These documents identify important risk factors that could cause the actual results to differ materially from those contained in the Company's projections or other forward-looking statements. All third-party marks—® and ™—are the property of their respective owners. Certain market and industry data has been obtained from third-party sources, which the Company believes are reliable, but the Company has not independently verified the information provided by third-party sources. Unless otherwise noted, market growth rates used in this presentation are estimates based on Company and third-party industry research.

## NON-GAAP FINANCIAL MEASURES

In this presentation, the Company's financial results and financial guidance are provided in accordance with accounting principles generally accepted in the United States (GAAP) and using certain non-GAAP financial measures. Management believes that presentation of operating results using non-GAAP financial measures provides useful supplemental information to investors and facilitates the analysis of the Company's core operating results and comparison of operating results across reporting periods. Management also uses non-GAAP financial measures to establish budgets and to manage the Company's business. Definitions of the non-GAAP financial measures and a reconciliation of the GAAP to non-GAAP financial results are provided in the Appendix to this presentation.

The Company does not provide forward-looking guidance on a GAAP basis for the measures on which it provides forward-looking non-GAAP guidance as the Company is unable to provide a quantitative reconciliation of forward-looking non-GAAP measures to the most directly comparable forward-looking GAAP measure, without unreasonable effort, because of the inherent difficulty in accurately forecasting the occurrence and financial impact of the various adjusting items necessary for such reconciliations that have not yet occurred, are dependent on various factors, are out of the Company's control, or cannot be reasonably predicted at the time of this presentation. Such adjustments include, but are not limited to, strategic realignment, costs related to amortization of intangibles from acquisitions, impairment and related charges, depreciation, equity compensation, tax benefits, and other adjustments. For example, stock-based compensation may fluctuate based on the timing of employee stock transactions and unpredictable fluctuations in the Company's stock price. Any associated estimate of these items and their impact on GAAP performance could vary materially.

# Progress

**Sam Raha**

PRESIDENT AND  
CHIEF EXECUTIVE OFFICER

# First quarter 2026 performance and takeaways

Advancing Cancer Care Continuum +  
preparing for multiple new test launches

## Strong Cancer Care Continuum test volume growth

Q1'26 revenue of \$200.4M, or 2%  
YOY; reflects YOY volume changes  
in:

- Cancer Care Continuum: 13%
- Mental Health: 7%
- Prenatal Health: (12)%

Reiterating 2026 financial guidance

## Investing ahead of a robust new product cycle

68.7% gross margins in Q1'26;  
+20 basis points YOY

Q1'26 adj operating expense\*  
increased \$7.9M YOY and reflects  
commercial growth investments

\$(4.5M) adj EBITDA\* and  
\$(0.09) adj EPS\* in Q1'26

Solid liquidity position; Access to  
~\$199M at end of Q1'26

## Advancing Cancer Care Continuum strategy

Launched initial clinical testing of  
Precise MRD (March'26)

New products (Q2'26):


- Disease specific MyRisk HCT panels (launched in April'26)
- AI-enhanced Prolaris prostate cancer test (expected to launch in June'26)

# Entering MRD market with a differentiated approach

## MARKET DRIVERS

Growing market awareness of the importance of ultra-sensitive detection

Community oncologist preference for comprehensive offering



Precise MRD is an ultra-sensitive, tissue informed assay that can detect ctDNA down to 1 part-per-million, enabling more confident clinical decision-making

## HIGHLIGHTS

- Complements Myriad Genetics' portfolio of tests across the Cancer Care Continuum
- Deploying dedicated MRD sales team targeting surgeons and oncologists
- Numerous prospective and retrospective studies and publications underway

### MOLECULAR RESIDUAL DISEASE TOTAL

TAM **\$21B**

EST. ANNUAL MARKET GROWTH **15-20%**

	MRD INDICATIONS			
	BREAST	CRC <sup>1</sup>	RENAL	OVARIAN & ENDOMETRIAL
TAM	<b>\$7B</b>	<b>\$5B</b>	<b>\$1B</b>	<b>\$2B</b>



The combination of test performance, comprehensive portfolio, and leadership in community medicine will enable Myriad to grow a leading MRD business

# Business Update

**Brian Donnelly**

CHIEF COMMERCIAL OFFICER

## Continue to drive strong Hereditary Cancer test growth; Launched Precise MRD



### First quarter 2026 and recent highlights

- Hereditary cancer testing continued double digit volume growth trend in Q1'26
- Solid Prolaris volume growth in Q1'26; expect launch of AI-enabled Prolaris in Q2'26
- Precise MRD momentum building; began clinical testing for select customers in March'26 with numerous clinical presentations at ASCO GU, ASCO GI, AACR, SABCS, and upcoming ASCO.

### Operational results:

**\$120.2M**

Q1'26 revenue

**~96K**

Q1'26 volume

### Key performance highlights:

#### Hereditary Cancer

**14%**

Volume growth<sup>1</sup>

**5%**

Revenue growth<sup>1</sup>

# On track for H2'26 launch of FirstGene multiple prenatal screen



## First quarter 2026 and recent highlights

- CIGNA updated its medical policy to cover expanded carrier screen panels, including Foresight Universal Plus, starting April'26
- FirstGene CONNECTOR study enrollment momentum accelerated in Q1'26 with expected completion of enrollment in H2'26
- FirstGene early access program launched in Q1'26; on-track for full commercial launch in H2'26

## Operational results:

**\$41.9M**

Q1'26 revenue

**~153K**

Q1'26 volume

## Key performance highlights:

### Prenatal

**(12)%**

Volume growth<sup>1</sup>

**(15)%**

Revenue growth<sup>1</sup>

# Maintaining leadership with disciplined level of investment and focus



## First quarter 2026 and recent highlights

- 39K clinicians ordered GeneSight in Q1'26
- Improvement in GeneSight average revenue per test reflects improved reimbursement trends (patient pay and biomarker coverage)
- Maintaining focus on expanding coverage and refining go-to-market strategies

### Operational results:

**\$38.3M**  
Q1'26 revenue

**~136K**  
Q1'26 volume

### Key performance highlights:

#### GeneSight

**7%**  
Volume growth<sup>1</sup>

**24%**  
Revenue growth<sup>1</sup>

# Taking actions designed to deliver strategic growth

Investing in the Cancer Care Continuum

## Focus on driving commercial success

### Improving share of voice with target customers

Meaningfully increased field sales team size and actively improving sales training, enablement, and customer targeting

### Expanding demand generation capabilities

Continuing to build and refine our capabilities to educate providers and patients across the product portfolio

### Preparing for critical product launches

Driving cross-functional new product launch excellence process to ensure rapid awareness and customer adoption

# Financial Update

**Ben Wheeler**


CHIEF FINANCIAL OFFICER

# First quarter key volume growth drivers


## Select test volume and growth rates

All figures in thousands, except growth rates

### Cancer Care Continuum\*



### Mental Health



## Additional highlights:

Within Cancer Care Continuum:


- Hereditary Cancer testing volume grew 14% YOY in Q1'26
- Prolaris and Precise Tumor generated positive YOY volume growth in Q1'26

\*Logos do not reflect the complete list of products included in the Cancer Care Continuum category.

# First quarter 2026 financial performance

Investing ahead of new product cycle

All figures in millions, except per share amounts and percentages



\*GAAP to non-GAAP reconciliations for Q1'25 and Q1'26 can be found in the Appendix.

# Strong gross profit and healthy liquidity position

## Gross Profit

Generated approximately

**\$138M**

in Q1'26

## Adjusted EBITDA<sup>1</sup>

Generated a loss of

**\$5M**

in Q1'26

## Liquidity position<sup>2</sup>

Access to

**~\$199M**

As of March 31, 2026

## Additional highlights:

Q1'26 adj operating cash flow<sup>1</sup> was \$(13M)

Q1'26 adj free cash flow<sup>1</sup> was \$(20M)

# Reaffirming 2026 financial guidance

All figures in millions, except percentages

	2026 FINANCIAL GUIDANCE	COMMENTS
Total Revenue	<b>\$860 - 880</b>	Reiterate the full year 2026 revenue range, reflecting current business trends.  Expect 2H'26 revenue to be greater than 1H'26
Adjusted Gross Margin*	<b>68% - 69%</b>	Gross margins expected to fluctuate quarter to quarter given product mix and pricing trends.
Adjusted EBITDA*	<b>\$37 - 49</b>	



\*The company does not forecast GAAP gross margin, because it cannot predict certain elements that are included in reported GAAP results. See the statement on Non-GAAP Financial Measures at the beginning of this presentation and the Appendix to this presentation for more information about the use of non-GAAP financial measures.

Assumes currency rates as of May 5, 2026.

# Catalysts to watch in 2026E

## HCT

- ✓ Launch of MyRisk Disease Specific Panels; H1'26
- ✓ Increase sample volume growth rate

## Prostate Cancer

- Launch Prolaris AI test; Q2'26
- Prolaris meta-analysis publication; H2'26

## Precise MRD

- ✓ Initiate commercial testing for select customers; March'26
- MoIDx submissions for Breast; Q3'26, Renal and CRC; H2'26
- Breast publication, MONITOR study; H2'26
- CRC data as part of pan-cancer publication, MONSTAR3 study; H2'26

## Prenatal Health

- ✓ Report out on FirstGene CONNECTOR study; H1'26
- Commercial launch of FirstGene; H2'26

## Cancer Care Continuum

- Increase sample volume growth
- New strategic partnerships

# Q&A

# Appendix

# Reconciliation of GAAP to Non-GAAP Financial Measures for the Three Months Ended March 31, 2026 and 2025 – Adjusted Gross Margin

(unaudited data in millions)

	<b>Three months ended March 31,</b>	
	<b>2026</b>	<b>2025</b>
<b>Adjusted Gross Margin</b>		
Gross Profit	\$ 137.6	\$ 134.2
Acquisition - amortization of intangible assets <sup>(1)</sup>	0.1	0.3
Equity compensation <sup>(2)</sup>	0.2	0.3
Other adjustments <sup>(3)</sup>	—	0.3
Adjusted Gross Profit	<u>\$ 137.9</u>	<u>\$ 135.1</u>
Adjusted Gross Margin	<u>68.8 %</u>	<u>69.0 %</u>

(1) Represents recurring amortization charges resulting from the acquisition of intangible assets.

(2) Consists of the non-cash equity-based compensation provided to Myriad Genetics employees.

(3) Other one-time non-recurring expenses.

# Reconciliation of GAAP to Non-GAAP Financial Measures for the Three Months Ended March 31, 2026 and 2025 – Adjusted Operating Expenses

(unaudited data in millions)

	<b>Three months ended March 31,</b>	
	<b>2026</b>	<b>2025</b>
<b>Adjusted Operating Expenses</b>		
Operating Expenses	\$ 168.3	\$ 163.2
Acquisition - amortization of intangible assets <sup>(1)</sup>	(6.4)	(8.8)
Goodwill and long-lived asset impairment <sup>(2)</sup>	(5.4)	—
Equity compensation <sup>(3)</sup>	(6.3)	(9.2)
Real estate optimization <sup>(4)</sup>	—	(3.0)
Strategic realignment <sup>(5)</sup>	(1.7)	(1.7)
Other adjustments <sup>(6)</sup>	—	0.1
<b>Adjusted Operating Expenses</b>	<b>\$ 148.5</b>	<b>\$ 140.6</b>

## Reconciliation of GAAP to Non-GAAP Financial Measures for the Three Months Ended March 31, 2026 and 2025 – Adjusted Operating Expenses (Cont.)

- (1) Represents recurring amortization charges resulting from the acquisition of intangible assets.
- (2) Expense related to goodwill and long-lived asset impairment. For the three months ended March 31, 2026, consists of \$5.4 million of impairment expense associated with our Women's Health reporting unit and certain intangible assets.
- (3) Consists of the non-cash equity-based compensation provided to Myriad Genetics employees and directors.
- (4) Costs related to real estate initiatives. For the three months ended March 31, 2025, consists of additional rent as a result of the build-out of our new laboratories in Salt Lake City, Utah and South San Francisco, California, while maintaining our current laboratories in those locations and testing and set-up costs for equipment in our new facilities.
- (5) Costs related to strategic realignment of the company including severance and consulting fees. During the three months ended March 31, 2026, management determined that severance costs that had previously been reported in other-one-time expenses should be reported as part of our strategic realignment efforts. Consequently \$1.7 million in severance costs that were reported as other adjustments in our reconciliations of GAAP to Non-GAAP financial measures for the three months ended March 31, 2025 were reclassified to strategic realignment in this reconciliation.
- (6) Other one-time non-recurring adjustments. See also Note 5 above regarding reclassification of other adjustments to strategic realignment.

# Reconciliation of GAAP to Non-GAAP Financial Measures for the Three Months Ended March 31, 2026 and 2025 – Adjusted Net Loss

(unaudited data in millions, except per share amounts)

	Three months ended March 31,	
	2026	2025
<b>Adjusted Net Loss<sup>(1)</sup></b>		
Net Loss	\$ (34.1)	\$ (0.1)
Acquisition - amortization of intangible assets <sup>(2)</sup>	6.5	9.1
Goodwill and long-lived asset impairment <sup>(3)</sup>	5.4	—
Equity compensation <sup>(4)</sup>	6.5	9.5
Real estate optimization <sup>(5)</sup>	—	3.0
Strategic realignment <sup>(6)</sup>	1.7	1.7
Other adjustments <sup>(7)</sup>	—	0.2
Uncertain tax benefit <sup>(8)</sup>	—	(28.7)
Tax adjustments <sup>(9)</sup>	5.8	2.2
<b>Adjusted Net Loss</b>	<b>\$ (8.2)</b>	<b>\$ (3.1)</b>
<b>Weighted average shares outstanding:</b>		
Diluted	93.7	91.4
<b>Adjusted Loss Per Share</b>		
Diluted	\$ (0.09)	\$ (0.03)

## Reconciliation of GAAP to Non-GAAP Financial Measures for the Three Months Ended March 31, 2026 and 2025 – Adjusted Net Loss (Cont.)

- (1) To determine Adjusted Loss Per Share.
- (2) Represents recurring amortization charges resulting from the acquisition of intangible assets.
- (3) Expense related to goodwill and long-lived asset impairment. For the three months ended March 31, 2026, consists of \$5.4 million of impairment expense associated with our Women's Health reporting unit and certain intangible assets.
- (4) Consists of the non-cash equity-based compensation provided to Myriad Genetics employees and directors.
- (5) Costs related to real estate initiatives. For the three months ended March 31, 2025, consists of additional rent as a result of the build-out of our new laboratories in Salt Lake City, Utah and South San Francisco, California, while maintaining our current laboratories in those locations and testing and set-up costs for equipment in our new facilities.
- (6) Costs related to strategic realignment of the company including severance and consulting fees. During the three months ended March 31, 2026, management determined that severance costs that had previously been reported in other-one-time expenses should be reported as part of our strategic realignment efforts. Consequently \$1.7 million in severance costs that were reported as other adjustments in our reconciliations of GAAP to Non-GAAP financial measures for the three months ended March 31, 2025 were reclassified to strategic realignment in this reconciliation.
- (7) Other one-time non-recurring adjustments. See also Note 6 above regarding reclassification of other adjustments to strategic realignment.
- (8) Consists of the release of unrecognized tax benefits and the recognition of valuation allowances for the three months ended March 31, 2025. The unrecognized tax benefits released were primarily related to tax years under Joint Committee on Taxation review, which upon conclusion of the review were remeasured or released.
- (9) Tax expense or benefit due to non-GAAP adjustments, differences between stock compensation recorded for book purposes as compared to the allowable tax deductions, and valuation allowance recognized against federal and state deferred tax assets in the United States. As of March 31, 2026, a valuation allowance of \$109.6 million was not recognized for non-GAAP purposes given our historical and forecasted positive earnings performance. As of March 31, 2025, a valuation allowance of \$67.0 million was not recognized for non-GAAP purposes given the company's historical and forecasted positive earnings performance.

# Reconciliation of GAAP to Non-GAAP Financial Measures for the Three Months Ended March 31, 2026 and 2025 – Adjusted EBITDA

(unaudited data in millions)

	Three months ended March 31,	
	2026	2025
<b>Adjusted EBITDA</b>		
Net Loss	\$ (34.1)	\$ (0.1)
Acquisition - amortization of intangible assets <sup>(1)</sup>	6.5	9.1
Depreciation expense <sup>(2)</sup>	4.7	5.1
Goodwill and long-lived asset impairment <sup>(3)</sup>	5.4	—
Equity compensation <sup>(4)</sup>	6.5	9.5
Real estate optimization <sup>(5)</sup>	—	3.0
Strategic realignment <sup>(6)</sup>	1.7	1.7
Interest expense, net of interest income <sup>(7)</sup>	3.4	0.5
Other adjustments <sup>(8)</sup>	1.4	0.4
Uncertain tax benefits <sup>(9)</sup>	—	(28.7)
Income tax (benefit) expense <sup>(10)</sup>	—	(0.6)
<b>Adjusted EBITDA</b>	<b>\$ (4.5)</b>	<b>\$ (0.1)</b>

## Reconciliation of GAAP to Non-GAAP Financial Measures for the Three Months Ended March 31, 2026 and 2025 – Adjusted EBITDA (Cont.)

- (1) Represents recurring amortization charges resulting from the acquisition of intangible assets.
- (2) Consists of depreciation expense recognized during the period.
- (3) Expense related to goodwill and long-lived asset impairment. For the three months ended March 31, 2026, consists of \$5.4 million of impairment expense associated with our Women's Health reporting unit and certain intangible assets.
- (4) Consists of the non-cash equity-based compensation provided to Myriad Genetics employees and directors.
- (5) Costs related to real estate initiatives. For the three months ended March 31, 2025, consists of additional rent as a result of the build-out of our new laboratories in Salt Lake City, Utah and South San Francisco, California, while maintaining our current laboratories in those locations and testing and set-up costs for equipment in our new facilities.
- (6) Costs related to strategic realignment of the company including severance and consulting fees. During the three months ended March 31, 2026, management determined that severance costs that had previously been reported in other-one-time expenses should be reported as part of our strategic realignment efforts. Consequently \$1.7 million in severance costs that were reported as other adjustments in our reconciliations of GAAP to Non-GAAP financial measures for the three months ended March 31, 2025 were reclassified to strategic realignment in this reconciliation.
- (7) Derived from interest expense and interest income from the Condensed Consolidated Statements of Operations.
- (8) Other one-time non-recurring expenses. For purposes of adjusted EBITDA, this includes Other adjustments described in the Adjusted Net Loss table above as well as the amounts reported as Other income (expense) in the Condensed Consolidated Statement of Operations. See also Note 6 above regarding the reclassification of other adjustments to strategic realignment.
- (9) Consists of the release of unrecognized tax benefits and the recognition of valuation allowances for the three months ended March 31, 2025. The unrecognized tax benefits released were primarily related to tax years under Joint Committee on Taxation review, which upon conclusion of the review were remeasured or released.
- (10) Derived from income tax (benefit) expense from the Condensed Consolidated Statement of Operations, net of the adjustment for unrecognized tax benefits described in Note 9 above.

# Reconciliation of GAAP to Non-GAAP Financial Measures for the Three Months Ended March 31, 2026 and 2025 – Adjusted Free Cash Flow

(unaudited data in millions)

	Three months ended March 31,	
	2026	2025
<b>Adjusted Operating and Free Cash Flow</b>		
Net Cash Used in Operating Activities	\$ (15.7)	\$ (16.3)
Real estate optimization <sup>(1)</sup>	—	4.0
Strategic realignment <sup>(2)</sup>	2.3	1.7
Other adjustments <sup>(3)</sup>	—	0.2
Adjusted Operating Cash Flow	\$ (13.4)	\$ (10.4)
Capital expenditures <sup>(4)</sup>	(5.4)	(5.3)
Capitalization of internal-use software costs <sup>(4)</sup>	(1.1)	(3.0)
<b>Adjusted Free Cash Flow</b>	<b>\$ (19.9)</b>	<b>\$ (18.7)</b>

(1) The cash flow effect of real estate optimizations, excluding non-cash items such as accelerated depreciation.

(2) Strategic realignment includes the cash paid for those costs in the related periods. During the three months ended March 31, 2026, management determined that severance costs that had previously been reported in other one-time expenses should be reported as part of our strategic realignment efforts. Consequently \$1.7 million in severance costs that were reported as other adjustments in our reconciliations of GAAP to Non-GAAP financial measures for the three months ended March 31, 2025 were reclassified to strategic realignment in this reconciliation.

(3) The cash flow effect of other one-time non-recurring expenses. See also Note 2 above regarding the reclassification of other adjustments to strategic realignment.

(4) Derived from the Condensed Consolidated Statements of Cash Flows.